4 news items
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
ICU
10 Jun 24
. She served on the Quality, Safety & Patient Experience and the Government & Compensation Executive & Strategy committees. Prior
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
ICU
7 Jun 24
organs without immunosuppression, thereby opening its potential for wide application. We have a proven safety track record with SCD in treating patients
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
ICU
14 May 24
medical sites in this trial that is evaluating the safety and efficacy of our Selective Cytopheretic Device Adult (SCD-ADULT) in the significantly larger
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
ICU
17 Apr 24
. children's hospitals. "In our NEUTRALIZE-AKI pivotal clinical trial, which is evaluating the safety and efficacy of our Selective
- Prev
- 1
- Next